By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Smart inhalers are becoming more popular as a means of managing and treating respiratory illnesses. A growing number of companies are using digital technologies into their products to improve asthma and chronic obstructive pulmonary disease (COPD) management, as well as pharmaceutical effectiveness.
A handful of products are already on the market, and several more are expected to get regulatory approval and join the market in the coming years. New smart inhalers’ could improve treatment options and help scientists figure out what’s causing the global epidemic.
The Europe Smart Inhalers Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2029, registering a CAGR of XX% from 2024 to 2030.
FindAir, a respiratory health startup established in Poland, will start selling its digital inhaler add-on to European customers. The FindAir One device connects wirelessly to a companion mobile and web app for both patients and clinicians. For the former, the app captures data passively with each usage to track the frequency of a user’s symptoms, as well as other pertinent data like pollen level, air quality, and whether any overlaps exist. Physicians, on the other hand, can look at the data to see how the user is doing when they are away from the office.
The Smart Inhaler from Adherium Ltd has been selected for the myAirCoach programme, which is part of the European Union’s Horizon Framework for Research and Innovation.
Novartis has received European Commission approval for Enerzair Breezhaler, which includes the first digital companion (sensor and app) that may be prescribed alongside an asthma therapy in the EU. Enerzair Breezhaler, a once-daily LABA/long-acting muscarinic antagonist (LAMA)/ICS fixed-dose combination, is the first LABA/LAMA/ICS fixed-dose combination available in the EU for these patients.
